“If you want to see what a cure looks like, you already have,” said Tom Whitehead as his daughter Emily joined him at the lectern at the public hearing of the FDA Oncologic Drugs Advisory Committee July 12.
“She’s standing right beside me.”
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in oncology were thinking.
